This story reports on a very preliminary study in only 13 women. If you’re going to do this, you need to include many more caveats and limitations than were provided in this story.
The research reported on here isn’t strong enough to back up the story’s provocative claims.
A story that includes the line “Anyone remember fen-phen?” should be more circumspect about touting the benefits of a drug that has yet to be tested on a single person.
This investor-focused story about a company-funded drug trial had questionable news value.
Because this project lost its foundation funding on July 1, 2013, the publisher is unable to pay any of the terrific reviewers pictured at upper right on this page. We hope this is only a temporary situation as we continue to pursue other funding sources. Meantime, the publisher will continue to write frequently on the Health News Watchdog blog on this site.
Thank you for your continued interest.
It’s difficult to do an overview of melanoma drug research in a relatively brief story. But this story did a solid job.